Source: Cleveland BioLabs, Inc.
Posted: January 10, 2007 12:14 PM ET
Summary:
Cleveland BioLabs, Inc. (Nasdaq: CBLI)(BSE: CFB), announced that through its research in the area of radiation protection, the Company has discovered a unique property of its Protectans 600 series, which has lead to a major breakthrough in the stem cell arena. A single administration of CBLB612, the lead compound in the Protectans 600 series, resulted in a three-fold increase in the number of progenitor (originator) stem cells in mouse bone marrow within 24 hours after administration. Moreover, the number of these stem cells in peripheral blood was increased 10-fold within four days of administration. This research indicates that CBLB612 and other compounds in the 600 series are not only potent stimulators of bone marrow stem cells, but also cause their mobilization and proliferation throughout the blood. This discovery opens a new way to approach a broad spectrum of human diseases, some of which currently lack effective treatment.
No comments:
Post a Comment